Ramino-Bio

Company Overview

Snapshot

Founded in September 2018, Ramino-Bio operated with 1–10 employees. The company secured funding in one round from six investors, including Johnson & Johnson Innovation and RMGP Biopharma Investment Fund. Ramino-Bio ceased operations in November 2025.

Business overview

Ramino-Bio was a biopharmaceutical company focused on developing an oral drug for cardio-metabolic diseases and rare Maple Syrup Urine Disease (MSUD). The company's technology aimed to address unmet needs in metabolic diseases related to elevated Branched-chain amino acids (BCAA) and was in preclinical stages with a druggable lead compound demonstrating in-vivo efficacy. Ramino-Bio operated within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, targeting the healthcare and life sciences industries.

Company Intelligence Q&A

When was Ramino-Bio founded?

Ramino-Bio was founded in September 2018.

What is Ramino-Bio's primary focus?

Ramino-Bio focuses on developing an oral drug for treating cardio-metabolic diseases and rare Maple Syrup Urine Disease (MSUD).

What is the current operational status of Ramino-Bio?

Ramino-Bio ceased to operate in November 2025.

Which investors participated in Ramino-Bio's funding round?

In September 2018, Ramino-Bio received funding from investors including Johnson & Johnson Innovation.

What stage of development was Ramino-Bio's lead candidate in?

Ramino-Bio's lead candidate was in preclinical stages, with first-in-human studies planned within 18 months of its description.